Buffer-Free Lidocaine Bladder Composition for Cystitis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystitis, particularly interstitial cystitis, often use compositions containing buffering agents that can irritate the bladder wall, leading to pain and discomfort in patients, and there is a need for pharmaceutical compositions that do not rely on such agents.
Innovation Solution
Aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate, formulated without buffering agents, are developed to maintain a pH that supports the formation of alkalized lidocaine, providing pain relief and promoting healing of the bladder wall.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If buffering agents are included in the composition to maintain pH, then pH stability is improved, but patient irritation and pain increase
Solution Approach 1:
The patent removes buffering agents from the composition entirely, extracting the harmful component while maintaining pH stability through alternative means (pH adjusting agents like sodium hydroxide or potassium hydroxide brought to a specific pH range without additional buffers). This resolves the contradiction by eliminating the source of irritation while preserving the necessary pH conditions for lidocaine effectiveness.
2Object-affected harmful factors
If lidocaine is used to relieve bladder pain, then pain relief is improved, but the composition requires specific pH conditions that may conflict with stability
Solution Approach 1:
The patent optimizes the pH parameter of the composition to a specific range (pH 6.0-8.5, preferably pH 7.0-8.0) where lidocaine achieves adequate alkalization for pain relief while maintaining compositional stability. This parameter optimization resolves the contradiction by finding the optimal pH window that satisfies both therapeutic effectiveness and chemical stability requirements.
Data Source
AI summary
Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate (or a pharmaceutically acceptable salts of any thereof) and water, as well as methods of making such aqueous pharmaceutical compositions, and therapeutic methods using them.